Skip to main content
Premium Trial:

Request an Annual Quote

Bayer to Evaluate Protagen's UNIarray

NEW YORK (GenomeWeb News) – Protagen today said that Bayer HealthCare will evaluate the firm’s UNIarray technology for discovering biomarkers for patient stratification and predictive diagnosis of atrial fibrillation.
 
Protagen’s UNIarray is designed to help develop diagnostics based on indication-specific autoantibody patterns in blood samples. The firm said that such autoantibody patterns are present not only in several autoimmune diseases but also in cancer, neurodegenerative disorders, and some healthy individuals.
 
Bayer HealthCare is currently studying atrial fibrillation after heart surgery, a condition that cannot be predicted with current diagnostic tools, Protagen said.
 
The firms did not say how long the evaluation period would last, and they did not disclose any financial terms of the pact.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more